U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...
Yonhap News English on MSN7h
Celltrion gets U.S. approval for allergic asthma biosimilar
The U.S. Food and Drug Administration (FDA) approved Celltrion's Omlyclo, a biosimilar drug to Xolair, for treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps ...
Punjab News Express4h
S.Korean drugmaker Celltrion gets USFDA approval for allergic asthma biosimilar
SEOUL: Celltrion, a major South Korean biopharmaceutical firm, said on Monday that its biosimilar for asthma and other chronic allergic diseases has obtained approval for sales in the US market.
The Pharma Letter21h
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...